(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
Russia Fields New Ulan-2 All-Terrain Tactical Vehicle- Creativity Revealed: A Survey of \Making Shocking Looks\ Cosmetics Item
- New findings suggest atmosphere could exist on exoplanet TOI-561b
- Are your hormones imbalanced? Doctors explain how to know if you need testing
- Steinmeier honours Italian 'guest workers' who rebuilt German economy
- How to sound like an astronaut as you follow the first human moon mission in more than half a century
- Distributed storage Answers for Information Reinforcement
- DEA seizes 1.7 million counterfeit fentanyl pills in Colorado storage unit
- Euclid space telescope sees gorgeous cosmic cloud | Space photo of the day for Nov. 18, 2025
